Myth vs Reality

Myth

Gaganyaan puts India ahead of China in space. Fact: China's Shenzhou programme first put humans in orbit in 2003, has a permanent space station (Tiangong) since 2022, and plans lunar crewed missions by 2030. Gaganyaan is India catching up with a 20-year gap. Myth: The mission will launch in 2026. Fact: the 2026 launch is the unmanned G1 test flight; the crewed H1 mission is targeted for 2027 — and ISRO has acknowledged that even this may slip if LVM3 reliability testing finds issues. Myth: ₹9,023 crore is a huge investment. Fact: NASA spent $30 billion (1961-1969) on Apollo in today's dollars; Gaganyaan is extraordinarily cost-efficient by comparison, continuing ISRO's tradition of doing more with less. Myth: Gaganyaan will immediately enable Indian space tourism. Fact: it is a government science and sovereignty mission, not a commercial one — private crewed missions from India are at least a decade away. The mission's core purpose is to establish India's technical credibility for future lunar and deep-space collaborations.

Myth

Rural Indian communities are more resilient and don't suffer from urban-style stress.** NMHS 2023 data shows comparable rates of depression and anxiety in rural and urban populations. Rural stress has different triggers (drought, debt, agrarian distress) but the neurological outcome — depression — is the same. **Myth: Suicide in rural India is primarily about economic crisis, not mental illness.** ICAR studies across Maharashtra, Karnataka, and MP show that 60-70% of farmer suicides involve co-occurring depressive disorder. Economic crisis is the trigger; untreated depression is the vulnerability. **Myth: Religious or traditional healing can substitute for clinical care.** Faith healing delays clinical diagnosis and treatment. Conditions treated early respond better; chronic untreated mental illness is harder to manage. **Fact:** Trained lay health workers (like ASHA workers after mental health training) can deliver effective psychological first aid and screen-and-refer services. Sangath's PREMIUM trial demonstrated outcomes equivalent to trained counsellors.

Myth

Biosimilars are inferior copies.** Fact: Regulatory agencies including the US FDA require biosimilars to demonstrate no clinically meaningful difference from the originator in safety and efficacy. Multiple clinical trials — including studies published in the New England Journal of Medicine — confirm biosimilar trastuzumab delivers identical breast cancer outcomes to Herceptin. **Myth: Indian biosimilars are only for low-income markets.** Fact: Biocon's biosimilar insulin and trastuzumab are approved and sold in the United States, Germany, France, and 70+ other countries. They are not a developing-world substitute; they are the same drug at a lower price. **Myth: Big Pharma will always maintain its advantage in biologics.** Fact: The 2025-2030 patent cliff covers over $180 billion in originator biologic revenue. Every dollar of that is contestable by biosimilar makers — and Indian companies are the best-positioned manufacturers outside Korea to contest it.

Myth

Gaganyaan is just a prestige project with no scientific value.** Fact: The programme builds institutional capability — re-entry systems, life support, crew extraction from sea — that India needs for Chandrayaan-4 sample return, the proposed Bharatiya Antariksha Station (2035), and future planetary missions. Human spaceflight engineering is the prerequisite for India's next 50 years of space ambitions. **Myth: France is providing the critical technology because India can't develop it.** Fact: ISRO is indigenising most systems. The French components (three specific life-support elements) are contributions to a broader system that ISRO developed. The partnership is a shortcut that saves 3-5 years, not a dependency. **Myth: Gaganyaan will compete with NASA/SpaceX.** Fact: Gaganyaan's first crewed mission is a 3-day orbital flight — the equivalent of what NASA did in 1961. India is not competing for the launch market; it is building the sovereign capability to participate as an equal partner in international human spaceflight programmes.

Myth

one genius drew a circle and finished the job in a day. Fact: positional notation, empty-place markers, and identity rules matured across centuries and regions with many anonymous copyists. Myth: Europeans resisted zero only out of superstition. Fact: accounting and calendar systems changed slowly because ledger standards and training pipelines are conservative, not merely because clergy disliked the void. Myth: zero is culturally neutral today. Fact: Unicode, floating-point standards, and classroom language still encode debates about negative roots and division rules that Brahmagupta already formalised. Separating myth from scholarship helps students see mathematics as cumulative human work rather than a trivia quiz about names.

Myth

every big flare means a Carrington-level blackout tomorrow. Fact: Earth needs a fast coronal mass ejection with southward interplanetary magnetic field sustained long enough to open the magnetosphere and drive ring current growth; many flares miss Earth or glance past with modest effects. Myth: auroras prove danger to humans outdoors. Fact: auroras are light shows; the infrastructure risk is geomagnetically induced currents in conductors, not radiation at sea level for brief storms. Myth: developing countries can ignore space weather because satellite counts are lower. Fact: long transmission lines at mid latitudes can couple strongly, and GNSS jamming from scintillation hurts logistics and timing everywhere. Clear myths help utilities spend budgets on transformer monitoring rather than panic bunkers.

Myth

Mental illness is a 'Western' problem.** NMHS 2023 data shows that rural India has comparable prevalence rates to urban India for severe mental illness; depression in rural women tied to domestic violence is actually higher than urban rates. **Myth: Mental health conditions are character weaknesses.** Decades of neuroscience have established that depression, schizophrenia, and OCD are medical conditions with biological components — not failures of willpower or spiritual weakness. **Myth: Religious healing is an alternative treatment.** 60% of rural patients first seek religious healers. Delay in receiving clinical treatment for severe mental illness worsens prognosis significantly — conditions that are treatable at early stage become chronic. **Fact:** India's Mental Healthcare Act 2017 established the right to treatment and prohibited solitary confinement in mental institutions — but enforcement remains patchy. Patients continue to be chained in some faith-healing centres despite these prohibitions.

Myth

Mindfulness is a Buddhist religious practice you have to convert to follow.** The technique can be practised as a secular skill; the Buddha himself emphasised ehipassiko — 'come and see' — over belief. Kabat-Zinn deliberately tested this: patients at UMass Medical School with no Buddhist background showed clinical improvements identical to those of experienced practitioners. **Myth: 10 minutes a day with an app produces the same benefits as a 10-day vipassana course.** Davidson's neuroimaging shows dose-dependent effects: long-term retreat practitioners with 10,000+ hours of practice show structural brain changes — increased grey matter density in the insula and prefrontal cortex — that short app sessions do not produce. **Myth: Mindfulness is universally beneficial.** Clinical literature documents 'meditation-induced adverse events' — anxiety spikes, dissociation, and trauma re-emergence — in a minority of practitioners; this is not well-advertised in the consumer industry. **Myth: Mindfulness alone is a substitute for therapy in moderate-to-severe depression.** MBCT works as adjunct, not stand-alone, treatment for diagnosed conditions. **Fact: Even short, regular practice reduces measurable stress markers** like cortisol and improves attentional control on standardised tests. **Fact: The Buddha's framework included ethical conduct (sila) and wisdom (panna) as inseparable from concentration (samadhi)** — removing the first two and keeping only the third changes what the practice does over decades, even if a single session looks the same.

Myth

The Arthashastra is the Indian equivalent of The Prince — a manual on ruthless power.** The Arthashastra is far broader than Machiavelli: a third of it is devoted to praja-sukha (people's welfare), administration of taxation, weights and measures, public health, agricultural policy, and judicial procedure. Treating it as a ruthlessness manual is reading 30% of the book. **Myth: 'Sama, dana, danda, bheda' is Chanakya's signature foreign-policy doctrine.** The four-fold method long predates Chanakya and appears across many Sanskrit political texts; Chanakya systematised it but did not invent it. **Myth: Most quotes attributed to Chanakya on WhatsApp are his.** The vast majority — including viral aphorisms on women, enemies, and money — are misattributed or invented; many circulate from the much later Chanakya Niti, a different compilation assembled several centuries after Chanakya's death. **Fact: The Arthashastra contains detailed instructions on espionage, counter-intelligence, double agents, and disinformation campaigns** that are strikingly modern, including the use of 'poison girls' (vishakanya) as intelligence assets — a concept that surprised Western intelligence historians when they first encountered the text. **Fact: It is explicit on a ruler's duty to ensure rule of law, including against the king's own officers — a normative principle Machiavelli does not match.**

Myth

vegetarian eating is automatically complete. Fact: it can be excellent when B12, iron, zinc, and omega-three pathways are planned with fortified foods or supplements. Myth: dal and spinach alone fix iron. Fact: absorption rules dominate; tea timing and vitamin C pairing matter more than volume alone. Myth: only the poor are deficient. Fact: affluent vegetarians often show low B12 while affluent office workers show low vitamin D. Naming myths reduces blame and redirects families toward cheap fixes like weekly IFA formats and dairy fortification once regulations bite.

Myth

India is the world's pharmacy, so domestic shortages are impossible. Fact: India is indeed the largest generic exporter but is structurally import-dependent on bulk APIs, especially from China. The 68% API import share creates a real domestic vulnerability that the 2020 COVID supply shock exposed and the 2026 shortage demonstrates again. Myth: shortages affect only government hospitals because of inefficiency. Fact: a 2024 study in Lancet Regional Health Southeast Asia found that 38% of India's private retail pharmacies also faced periodic stock-outs of essential medicines. The shortages cross sectors but the burden falls heaviest on the poor in government hospitals. Myth: generic drugs are unsafe and the shortages are about quality issues. Fact: generic drugs in India must clear the same CDSCO bioequivalence and quality standards as branded products. The 2026 shortages are about procurement and supply chain failure, not quality. Myth: Jan Aushadhi has solved India's medicine affordability problem. Fact: Jan Aushadhi has reduced prices for those who can reach a store and find stock — but as the 2026 data shows, 80% of stores currently have at least one essential drug stock-out. Coverage is wide, reliability is not. Myth: API self-reliance is round the corner. Fact: the PLI bulk drug scheme is genuinely shifting the needle, but at current pace will not hit the under-30% import target before 2030.

Myth

Indian hospitals are cheap because quality is low.** Fact: JCI accreditation — the global gold standard for hospital safety and quality — is held by 75+ Indian hospitals, more than any other Asian nation except Thailand. Multiple peer-reviewed studies published in the Lancet and BMJ have documented outcomes at Apollo and Narayana Health equal to or better than UK NHS outcomes for comparable procedures. **Myth: Only poor patients choose India.** Fact: A growing proportion of medical tourists are middle-class patients from UK, Canada, and Australia who face long wait times at home (the average NHS wait for a hip replacement is 18 months; Apollo delivers it in 3 days). **Myth: Medical tourism benefits only the private sector.** Fact: AIIMS New Delhi treats over 50,000 international patients per year, mostly from South Asian neighbours, at near-public rates. Government hospitals capture a significant fraction of lower-income medical tourists, effectively providing subsidised care to neighbouring-country nationals.

Myth

AI chatbots can treat depression.** Published research on Wysa and similar tools shows statistically significant reductions in mild anxiety and subclinical depression. Severe depression, suicidality, bipolar disorder, and psychosis require human clinical care — and can be made worse by delayed detection through app-first triage. Apps are step-one tools, not replacements. **Myth: Digital mental health reaches the most vulnerable.** The data is clear: app users skew urban, young, English-literate, and employed. The 83% treatment gap is concentrated in exactly the demographics that mental health apps don't reach. **Fact: Apps fill a genuine pre-clinical gap.** For the estimated 150-200 million Indians with sub-clinical stress, relationship difficulties, or adjustment issues — not yet diagnosable but struggling — self-guided apps offer accessible, affordable, stigma-reduced tools that physical clinics cannot offer at scale. **Fact: Outcome data is uneven.** Only Wysa and YourDOST have published peer-reviewed efficacy studies; most other apps make marketing claims without RCT data.